Table 4 Results of multiple linear regression (B coefficents) exploring factors independently associated with HR-QoL
SF-36 Domains | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
PF | RP | BP | GH | VT | SF | RE | MH | PCS | MCS | |
∆-BODI ≥1 | − 13.21§ | − 12.39† | -- | − 11.91§ | − 12.13§ | − 10.59† | − 16.51§ | − 14.87# | -- | − 6.90† |
Female | − 10.76§ | − 15.86# | − 19.58# | − 10.55§ | − 14.77# | − 17.47# | − 13.33§ | -- | − 6.42# | − 4.24§ |
Fibromyalgia | − 30.07# | − 33.27# | − 26.19§ | − 24.24# | − 22.29§ | − 27.48§ | − 20.56† | − 25.31§ | − 10.56# | − 9.49† |
BDCAF | − 1.25† | − 2.11§ | − 2.493# | − 2.89# | − 2.91# | − 1.60† | − 1.83§ | − 1.91# | − 0.77§ | − 0.95# |
Age | − 0.51# | -- | − 0.58# | -- | -- | -- | -- | -- | − 0.16# | -- |
GC duration | -- | − 0.140# | -- | -- | -- | -- | − 0.09† | -- | − 0.03† | -- |
Major organ involvement | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Immunosuppressantsa | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |